Furiex Pharmaceuticals Inc (FURX) financial statements (2021 and earlier)

Company profile

Business Address 3900 PARAMOUNT PARKWAY
MORRISVILLE, NC 27560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2329352836 
Cash and cash equivalents2329352836 
Receivables6816315 
Prepaid expense0010 
Prepaid expense and other current assets0 
Total current assets:3038513152 
Noncurrent Assets
Property, plant and equipment00000 
Intangible assets, net (including goodwill)4949494949
Goodwill4949494949 
Restricted cash and investments   88 
Deferred costs11200 
Total noncurrent assets:5151515757 
TOTAL ASSETS:808810288109 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1212221918 
Accounts payable7716126 
Accrued liabilities556712 
Debt14106129 
Due to related parties11    
Total current liabilities:2723273127 
Noncurrent Liabilities
Long-term debt and lease obligation2832362831 
Long-term debt, excluding current maturities2832362831 
Liabilities, other than long-term debt15151600 
Due to related parties141515   
Other liabilities11100 
Total noncurrent liabilities:4247522932 
Total liabilities:6970795958 
Stockholders' equity
Stockholders' equity attributable to parent1118232950 
Common stock00000 
Additional paid in capital180175173170168 
Accumulated deficit(170)(157)(150)(141)(118) 
Total stockholders' equity:1118232950 
TOTAL LIABILITIES AND EQUITY:808810288109 

Income statement (P&L) ($ in millions)

3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Gross profit:61316339 
Operating expenses(18)(18)(23)(25)(29) 
Operating income (loss):(11)(5)(8)(22)10 
Nonoperating income
(Other Nonoperating income)
0  00 
Interest and debt expense(2)(2)(1)(1)(1) 
Income (loss) from continuing operations before income taxes:(13)(6)(9)(23)9 
Income tax expense(0)(0)(0)(0)(0) 
Net income (loss) available to common stockholders, diluted:(13)(7)(9)(23)9 

Comprehensive Income ($ in millions)

3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
12/31/2012
Q4
Net income (loss):(13)(7)(9)(23)9 
Comprehensive income (loss), net of tax, attributable to parent:(13)(7)(9)(23)9 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: